Abstract
The p53 protein has many biological effects and a high prevalence of mutations in human cancer. Pathologists use this biomarker in several different situations, to help for the differential diagnosis of reactive/dysplastic/benign/malignant lesions, to better characterize malignant tumours, and to help in predicting response to treatment. p53 status of dysplastic and borderline lesions can most often be assessed only by immunohistochemistry (IHC) since these microscopical lesions are too small for advanced molecular assays. p53 protein status determined by IHC has however a smaller sensitivity compared to TP53 status assessed by gene sequencing. This explains why p53 as a biomarker remains not so widely used by pathologists except for several well-defined indications detailed in this chapter. P63, a member of the p53 family, is also frequently used in diagnostic pathology as a differentiation marker and will be discussed in this chapter.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ali TZ, Epstein JI (2008) False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells. Am J Surg Pathol 32:1890–1895
Al-Maghraby H, Ghorab Z, Khalbuss W, Wong J, Silverman JF, Saad RS (2010) The diagnostic utility of CK5/6 and p63 in fine-needle aspiration of the breast lesions diagnosed as proliferative fibrocystic lesion. Diagn Cytopathol 40(2):141–147
Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J (2008) A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 47:600–607
Amin MB (2010) The 2009 version of the cancer protocols of the college of American pathologists. Arch Pathol Lab Med 134:326–330
Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR (1994) An evaluation of six antibodies for immunohistochemistry of mutant TP53 gene product in archival colorectal neoplasms. J Pathol 172:5–12
Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, Palacios J, Rakha EA, Richardson AL, Schmitt FC, Tan PH, Tse GM, Weigelt B, Ellis IO, Reis-Filho JS (2010) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24(2):157–167
Bani-Hani K, Martin IG, Hardie LJ, Mapstone N, Briggs JA, Forman D, Wild CP (2000) Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92:1316–1321
Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C (2001) p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 25:1054–1060
Bártek J, Bártková J, Lukás J, Stasková Z, Vojtĕsek B, Lane DP (1993) Immunohistochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 169:27–34
Berggren P, Steineck G, Adolfsson J, Hansson J, Jansson O, Larsson P, Sandstedt B, Wijkström H, Hemminki K (2001) p53 mutations in urinary bladder cancer. Br J Cancer 84:1505–1511
Bernardini S, Adessi GL, Billerey C, Chezy E, Carbillet JP, Bittard H (1999) Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas. J Urol 162:1496–1501
Bertheau P, Plassa F, Espié M, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de Thé H (2002) Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 360:852–854
Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espié M, Clot P, Servant JM, Misset JL, Marty M, Janin A (2005) Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 14:513–520
Bertheau P, Turpin E, Rickman DS, Espié M, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de Thé H (2007) Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen. PLoS Med 4:e90
Bevilacqua G, Bosman F, Dassesse T, Höfler H, Janin A, Langer R, Larsimont D, Morente MM, Riegman P, Schirmacher P, Stanta G, Zatloukal K, Caboux E, Hainaut P (2010) The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch 456:449–454
Brambilla E, Gazzeri S, Lantuejoul S, Coll JL, Moro D, Negoescu A, Brambilla C (1998) p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl2, Bax, and Waf1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 4:1609–1618
Bratthauer GL, Saenger JS, Strauss BL (2005) Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Histopathology 47:611–616
Choi SW, Levine JE, Ferrara JL (2010) Pathogenesis and management of graft-versus-host disease. Immunol Allergy Clin North Am 30:75–101
Coggi G, Bosari S, Roncalli M, Graziani D, Bossi P, Viale G, Buffa R, Ferrero S, Piazza M, Blandamura S, Segalin A, Bonavina L, Peracchia A (1997) p53 protein accumulation and TP53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 79:425–432
Colomer A, Erill N, Verdú M, Roman R, Vidal A, Cordon-Cardo C, Puig X (2003) Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas. Appl Immunohistochem Mol Morphol 11:130–137
de Moraes Schenka NG, Schenka AA, de Souza QL, de Almeida MM, Alvarenga M, Vassallo J (2006) p63 and CD10: reliable markers in discriminating benign sclerosing lesions from tubular carcinoma of the breast? Appl Immunohistochem Mol Morphol 14:71–77
Di Como CJ, Urist MJ, Babayan I, Drobnjak M, Hedvat CV, Teruya-Feldstein J, Pohar K, Hoos A, Cordon-Cardo C (2002) p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 8:494–501
Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S (2010) p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol 17:1398–1405
Eady RA, Cowen T (1977) Epidermal repair in lichen planus: a light and electron microscopical study. Clin Exp Dermatol 2:323–334
Fayallah EA, Hemida RA, Gamal AM, Abd Elhady E, Anwar KI, Nada NA, Sherif LS, Sayed-Ahmed MT (2010) Pretreatment study of P53 overexpression for selection of candidates for pelvic lymphadenectomy in clinical stage I endometrial carcinoma: a randomized-controlled study. Arch Gynecol Obstet 283(3):617–622
Ferrer-Luna R, Núñez L, Piquer J, Arias E, Dasí F, Cervio A, Arakaki N, Sevlever G, Celda B, Martinetto H (2010) Whole-genomic survey of oligodendroglial tumors: correlation between allelic imbalances and gene expression profiles. J Neurooncol 103(1):71–85
Fléjou JF, Svrcek M (2007) Barrett’s oesophagus – a pathologist’s view. Histopathology 50:3–14
Garg K, Leitao MM Jr, Wynveen CA, Sica GL, Shia J, Shi W, Soslow RA (2010) p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol 23:80–92
Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM (2006) Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 24:1037–1044
Hamelin R, Fléjou JF, Muzeau F, Potet F, Laurent-Puig P, Fékété F, Thomas G (1994) TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett’s esophagus. Gastroenterology 107:1012–1018
Harpaz N, Polydorides AD (2010) Colorectal dysplasia in chronic inflammatory bowel disease: pathology, clinical implications, and pathogenesis. Arch Pathol Lab Med 134:876–895
Harton AM, Wang HH, Schnitt SJ, Jacobs TW (2007) p63 immunocytochemistry improves accuracy of diagnosis with fine-needle aspiration of the breast. Am J Clin Pathol 128:80–85
Hodges KB, Lopez-Beltran A, Davidson DD, Montironi R, Cheng L (2010) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 41:155–162
Horne GM, Anderson JJ, Tiniakos DG, McIntosh GG, Thomas MD, Angus B, Henry JA, Lennard TW, Horne CH (1996) p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer 73:29–35
Ip PP, Cheung AN, Clement PB (2009) Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol 33:992–1005
Jacquemier J, Molès JP, Penault-Llorca F, Adélaide J, Torrente M, Viens P, Birnbaum D, Theillet C (1994) p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer 69:846–852
Janin A, Murata H, Leboeuf C, Cayuela JM, Gluckman E, Legrès L, Desveaux A, Varna M, Ratajczak P, Soulier J, de Thé H, Bertheau P, Socié G (2009) Donor-derived oral squamous cell carcinoma after allogeneic bone marrow transplantation. Blood 113:1834–1840
Janin-Mercier A, Saurat JH, Bourges M, Sohier J, Jean LD, Gluckman E (1981) The lichen planus like and sclerotic phases of the graft versus host disease in man: an ultrastructural study of six cases. Acta Derm Venereol 61:187–193
Jankowski JA, Odze RD (2009) Biomarkers in gastroenterology: between hope and hype comes histopathology. Am J Gastroenterol 104:1093–1096
Jia L, Liu Y, Yi X, Miron A, Crum CP, Kong B, Zheng W (2008) Endometrial glandular dysplasia with frequent TP53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 14:2263–2269
Kaye PV, Haider SA, Ilyas M, James PD, Soomro I, Faisal W, Catton J, Parsons SL, Ragunath K (2009) Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 54:699–712
Kaye PV, Haider SA, James PD, Soomro I, Catton J, Parsons SL, Ragunath K, Ilyas M (2010) Novel staining pattern of p53 in Barrett’s dysplasia–the absent pattern. Histopathology 57:933–935
Keller U, von Bubnoff N, Peschel C, Duyster J (2010) Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy. J Cell Mol Med 14:805–817
Keswani RN, Noffsinger A, Waxman I, Bissonnette M (2006) Clinical use of p53 in Barrett’s esophagus. Cancer Epidemiol Biomarkers Prev 15:1243–1249
Khoury MP, Bourdon JC (2010) The isoforms of the p53 protein. Cold Spring Harb Perspect Biol 2:a000927
Kohno H, Hiroshima K, Toyozaki T, Fujisawa T, Ohwada H (1999) p53 mutation and allelic loss of chromosome 3p, 9p of preneoplastic lesions in patients with nonsmall cell lung carcinoma. Cancer 85:341–347
Lambkin HA, Mothersill CM, Kelehan P (1994) Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. J Pathol 172:13–18
Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW, Lee JH, Bae DS, Kim BG (2010) p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review. Gynecol Oncol 116:533–538
Lehmann-Che J, André F, Desmedt C, Mazouni C, Giacchetti S, Turpin E, Espié M, Plassa LF, Marty M, Bertheau P, Sotiriou C, Piccart M, Symmans WF, Pusztai L, de Thé H (2010) Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist 15:246–252
Levine AJ, Oren M (2009) The first 30 years of p53: growing ever more complex. Nat Rev Cancer 9:749–758
Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM (2010) Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 5:442–447
Louis DN (1994) The TP53 gene and protein in human brain tumors. J Neuropathol Exp Neurol 53:11–21
Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D, Kogevinas M, Real FX (2005) P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 6:678–686
Marx A, Wandrey T, Simon P, Wewer A, Grob T, Reichelt U, Minner S, Simon R, Spehlmann M, Tigges W, Soehendra N, Seitz U, Seewald S, Izbicki JR, Yekebas E, Kaifi JT, Mirlacher M, Terracciano L, Fleischmann A, Raedler A, Sauter G (2009) Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum Pathol 40:166–173
Molinié V, Fromont G, Sibony M, Vieillefond A, Vassiliu V, Cochand-Priollet B, Hervé JM, Lebret T, Baglin AC (2004) Diagnostic utility of a p63/alpha-methyl-CoA-racemase (p504s) cocktail in atypical foci in the prostate. Mod Pathol 17:1180–1190
Nenutil R, Smardova J, Pavlova S, Hanzelkova Z, Muller P, Fabian P, Hrstka R, Janotova P, Radina M, Lane DP, Coates PJ, Vojtesek B (2005) Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. J Pathol 207:251–259
Nicholson AG, Gonzalez D, Shah P, Pynegar MJ, Deshmukh M, Rice A, Popat S (2010) Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 5:436–441
Odze RD (2006) Diagnosis and grading of dysplasia in Barrett’s oesophagus. J Clin Pathol 59:1029–1038
Odze RD, Riddell RH, Bosman FT, Carneiro F, Fléjou J-F, Geboes K et al (2010) Premalignant lesions of the digestive system. In: Bosman FT, Carneiro F, Hruban RH, Theise ND (eds) WHO classification of tumours of digestive system. IARC, Lyon
Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, Schüler D, Probst-Hensch NM, Yasargil MG, Yonekawa Y, Lütolf UM, Kleihues P, Ohgaki H (2004) Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol 108:49–56
Osamura RY (2009) Roles of pathologists in molecular targeted cancer therapy. J Cell Mol Med 13:4286–4290
Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ (2002) Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res 8:1117–1124
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747–752
Pezzella F, Micklem K, Turley H, Pulford K, Jones M, Kocialkowski S, Delia D, Aiello A, Bicknell R, Smith K (1994) Antibody for detecting p53 protein by immunohistochemistry in normal tissues. J Clin Pathol 47:592–596
Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM (2010) TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J Clin Oncol 28:5188–5196
Ponticiello A, Barra E, Giani U, Bocchino M, Sanduzzi A (2000) P53 immunohistochemistry can identify bronchial dysplastic lesions proceeding to lung cancer: a prospective study. Eur Respir J 15:547–552
Prasad GA, Bansal A, Sharma P, Wang KK (2010) Predictors of progression in Barrett’s esophagus: current knowledge and future directions. Am J Gastroenterol 105:1490–1502
Quddus MR, Sung CJ, Zheng W, Lauchlan SC (1999) p53 immunoreactivity in endometrial metaplasia with dysfunctional uterine bleeding. Histopathology 35:44–49
Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC (2002) p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol 55:936–939
Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Crowther D (1994) Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 69:609–612
Ribeiro-Silva A, Ramalho LN, Garcia SB, Brandão DF, Chahud F, Zucoloto S (2005) p63 correlates with both BRCA1 and cytokeratin 5 in invasive breast carcinomas: further evidence for the pathogenesis of the basal phenotype of breast cancer. Histopathology 47:458–466
Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, Ahren C, Correa P, Hamilton SR, Morson BC (1983) Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 14:931–968
Rodriguez FJ, Scheithauer BW, Burger PC, Jenkins S, Giannini C (2010) Anaplasia in pilocytic astrocytoma predicts aggressive behavior. Am J Surg Pathol 34:147–160
Saurat JH, Gluckman E (1977) Lichen-planus-like eruption following bone marrow transplantation: a manifestation of the graft-versus-host disease. Clin Exp Dermatol 2:335–344
Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA (2002) Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 26:1161–1168
Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M (2000) p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 157:1769–1775
Sikkema M, Kerkhof M, Steyerberg EW, Kusters JG, van Strien PM, Looman CW, van Dekken H, Siersema PD, Kuipers EJ (2009) Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett’s esophagus: a case–control study. Am J Gastroenterol 104:2673–2680
Socié G, Henry-Amar M, Bacigalupo A, Hows J, Tichelli A, Ljungman P, McCann SR, Frickhofen N, Van’t Veer-Korthof E, Gluckman E (1993) Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. N Engl J Med 329:1152–1157
Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol 27:1050–1055
Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, Della Porta G, Pierotti MA (1992) Deletions of 17p and TP53 mutations in preneoplastic lesions of the lung. Cancer Res 52:6079–6082
Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, Esrig D, Miyao N, Tsai YC, Lerner SP, Schmütte C, Yang AS, Cote R (1994) Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res 54:784–788
Ständer M, Peraud A, Leroch B, Kreth FW (2004) Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis. Cancer 101:1028–1035
Stiewe T (2007) The p53 family in differentiation and tumorigenesis. Nat Rev Cancer 7:165–168
Sun W, Zhang PL, Herrera GA (2002) p53 protein and Ki-67 overexpression in urothelial dysplasia of bladder. Appl Immunohistochem Mol Morphol 10:327–331
Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–475, discussion 475–477
Tabori U, Baskin B, Shago M, Alon N, Taylor MD, Ray PN, Bouffet E, Malkin D, Hawkins C (2010a) Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. J Clin Oncol 28:1345–1350
Tabori U, Shlien A, Baskin B, Levitt S, Ray P, Alon N, Hawkins C, Bouffet E, Pienkowska M, Lafay-Cousin L, Gozali A, Zhukova N, Shane L, Gonzalez I, Finlay J, Malkin D (2010b) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. J Clin Oncol 28:1995–2001
Tse GM, Tan PH, Moriya T (2009) The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol 62:407–413
Vojtĕsek B, Fisher CJ, Barnes DM, Lane DP (1993) Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer 67:1254–1258
Wagner U, Sauter G, Moch H, Novotna H, Epper R, Mihatsch MJ, Waldman FM (1995) Patterns of p53, erbB-2, and EGF-r expression in premalignant lesions of the urinary bladder. Hum Pathol 26:970–978
Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K (2002) p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 9:216–219
Wang W, Sun X, Epstein JI (2008) Partial atrophy on prostate needle biopsy cores: a morphologic and immunohistochemical study. Am J Surg Pathol 32:851–857
Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J Clin Oncol 27:5743–5750
Werling RW, Hwang H, Yaziji H, Gown AM (2003) Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Am J Surg Pathol 27:82–90
Wiesend WN, Parasuraman R, Li W, Farinola MA, Rooney MT, Hick SK, Samarapungavan D, Cohn SR, Reddy GH, Rocher LL, Dumler F, Lin F, Zhang PL (2010) Adjuvant role of p53 immunostaining in detecting BK viral infection in renal allograft biopsies. Ann Clin Lab Sci 40:324–329
Würl P, Taubert H, Meye A, Berger D, Lautenschläger C, Holzhausen HJ, Schmidt H, Kalthoff H, Rath FW, Dralle H (1997) Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies. J Cancer Res Clin Oncol 123:502–508
Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D (2000) p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404:99–103
Zhou M, Shah R, Shen R, Rubin MA (2003) Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells. Am J Surg Pathol 27:365–371
Acknowledgements
We thank our colleagues from several laboratories of pathology who kindly answered our survey: J. Brière, F. Capron, J.M. Coindre, A. Couvelard, J.F. Emile, K. Mokhtari, V. Paradis, M. Peuchmaur, M.C. Vacher-Lavenue, and L. Xerri.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
Bertheau, P. et al. (2013). p53 in the Clinic: A Pathologist’s View. In: Hainaut, P., Olivier, M., Wiman, K. (eds) p53 in the Clinics. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3676-8_17
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3676-8_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-3675-1
Online ISBN: 978-1-4614-3676-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)